A multicenter, Double-blind 58 week Rollover Study to assess the Safety and Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression.

Trial Profile

A multicenter, Double-blind 58 week Rollover Study to assess the Safety and Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Liafensine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms BMS TRUI
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Oct 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 13 Sep 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 24 Jul 2012 New source identified and integrated (Clinical Trials Registry - India, CTRI2012-07-002773).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top